COVID-19和高血压。

IF 2.1 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Journal of the Renin-Angiotensin-Aldosterone System Pub Date : 2020-04-01 DOI:10.1177/1470320320927851

Spoorthy Kulkarni, Bernadette L Jenner, Ian Wilkinson

{"title":"COVID-19和高血压。","authors":"Spoorthy Kulkarni, Bernadette L Jenner, Ian Wilkinson","doi":"10.1177/1470320320927851","DOIUrl":null,"url":null,"abstract":"Infection with SARS-Cov-2 is the causative agent of coronavirus disease 2019 (COVID-19), which the WHO has described as a pandemic. As of July 27th, 2020, this disease has killed more than 16.3 million people worldwide and it appears that underlying cardiovascular disease constitutes substantial comorbidity correlated with the clinical decline and adverse outcomes in COVID-19 patients. Preliminary reports stated that hypertension may be associated with increased risk of SARS-Cov-2 infection but it now appears that older age and hypertension-related comorbidities somewhat confound this relationship. However, following the initial findings of using RAAS blockers with a higher risk of SARS-Cov-2 infection and a more serious course of COVID-19, it is now recognized that no solid scientific results are available in humans to support them. The application of RAAS blockers care in patients with appropriate indications are widely recommended by major international research organizations.","PeriodicalId":17330,"journal":{"name":"Journal of the Renin-Angiotensin-Aldosterone System","volume":"21 2","pages":"1470320320927851"},"PeriodicalIF":2.1000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1470320320927851","citationCount":"45","resultStr":"{\"title\":\"COVID-19 and hypertension.\",\"authors\":\"Spoorthy Kulkarni, Bernadette L Jenner, Ian Wilkinson\",\"doi\":\"10.1177/1470320320927851\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Infection with SARS-Cov-2 is the causative agent of coronavirus disease 2019 (COVID-19), which the WHO has described as a pandemic. As of July 27th, 2020, this disease has killed more than 16.3 million people worldwide and it appears that underlying cardiovascular disease constitutes substantial comorbidity correlated with the clinical decline and adverse outcomes in COVID-19 patients. Preliminary reports stated that hypertension may be associated with increased risk of SARS-Cov-2 infection but it now appears that older age and hypertension-related comorbidities somewhat confound this relationship. However, following the initial findings of using RAAS blockers with a higher risk of SARS-Cov-2 infection and a more serious course of COVID-19, it is now recognized that no solid scientific results are available in humans to support them. The application of RAAS blockers care in patients with appropriate indications are widely recommended by major international research organizations.\",\"PeriodicalId\":17330,\"journal\":{\"name\":\"Journal of the Renin-Angiotensin-Aldosterone System\",\"volume\":\"21 2\",\"pages\":\"1470320320927851\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2020-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/1470320320927851\",\"citationCount\":\"45\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Renin-Angiotensin-Aldosterone System\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/1470320320927851\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Renin-Angiotensin-Aldosterone System","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1470320320927851","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 45

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

COVID-19 and hypertension.

查看原文本刊更多论文

COVID-19 and hypertension.

Infection with SARS-Cov-2 is the causative agent of coronavirus disease 2019 (COVID-19), which the WHO has described as a pandemic. As of July 27th, 2020, this disease has killed more than 16.3 million people worldwide and it appears that underlying cardiovascular disease constitutes substantial comorbidity correlated with the clinical decline and adverse outcomes in COVID-19 patients. Preliminary reports stated that hypertension may be associated with increased risk of SARS-Cov-2 infection but it now appears that older age and hypertension-related comorbidities somewhat confound this relationship. However, following the initial findings of using RAAS blockers with a higher risk of SARS-Cov-2 infection and a more serious course of COVID-19, it is now recognized that no solid scientific results are available in humans to support them. The application of RAAS blockers care in patients with appropriate indications are widely recommended by major international research organizations.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of the Renin-Angiotensin-Aldosterone System 医学-外周血管病

CiteScore

6.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： JRAAS is a peer-reviewed, open access journal, serving as a resource for biomedical professionals, primarily with an active interest in the renin-angiotensin-aldosterone system in humans and other mammals. It publishes original research and reviews on the normal and abnormal function of this system and its pharmacology and therapeutics, mostly in a cardiovascular context but including research in all areas where this system is present, including the brain, lungs and gastro-intestinal tract.